Medical technology company BD (Becton, Dickinson and Company) (NYSE: BDX) announced on Tuesday that it has introduced a next-generation glass prefillable syringe (PFS), designed in collaboration with leading pharmaceutical companies to meet the complex and evolving needs of vaccine manufacturing.

The company stated that the BD Effivax Glass Prefillable Syringe will benefit from a USD1.2bn, four-year investment that the company announced in late 2020 to expand and upgrade manufacturing capacity and technology for PFS.

BD added that it remains committed to maintaining robust capacity for PFS to help reduce the time and labour required for vaccine preparation with traditional vial formats, as it plans for the future of vaccinations, including mRNA and those used for COVID-19.

Eric Borin, worldwide president of BD Pharmaceutical Systems, commented: "As biopharmaceutical companies continue to rapidly grow their vaccine pipelines, demand for PFS is accelerating across the globe - given their proven ability to facilitate faster administration, support dose sparing and reduce vaccine waste."